October 2021 OSE Immunotherapeutics Presents New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019
October 2021 OSE Immunotherapeutics Announces New Research Collaboration with Léon Bérard Cancer Center
October 2021 OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 for BI 765063
October 2021 OSE Immunotherapeutics and Servier Announce First Option for Clinical Development of OSE-127
October 2021 OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® to Treat Brain Metastasis